BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32146420)

  • 1. Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats.
    Di Martino MT; Arbitrio M; Caracciolo D; Scionti F; Tagliaferri P; Tassone P
    Mol Ther Nucleic Acids; 2020 Jun; 20():73-85. PubMed ID: 32146420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.
    Tassone P; Di Martino MT; Arbitrio M; Fiorillo L; Staropoli N; Ciliberto D; Cordua A; Scionti F; Bertucci B; Salvino A; Lopreiato M; Thunarf F; Cuomo O; Zito MC; De Fina MR; Brescia A; Gualtieri S; Riillo C; Manti F; Caracciolo D; Barbieri V; Di Paola ED; Di Francesco AE; Tagliaferri P
    J Hematol Oncol; 2023 Jun; 16(1):68. PubMed ID: 37365583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates.
    Gallo Cantafio ME; Nielsen BS; Mignogna C; Arbitrio M; Botta C; Frandsen NM; Rolfo C; Tagliaferri P; Tassone P; Di Martino MT
    Mol Ther Nucleic Acids; 2016 Jun; 5(6):. PubMed ID: 27327137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.
    Di Martino MT; Gullà A; Gallo Cantafio ME; Altomare E; Amodio N; Leone E; Morelli E; Lio SG; Caracciolo D; Rossi M; Frandsen NM; Tagliaferri P; Tassone P
    PLoS One; 2014; 9(2):e89659. PubMed ID: 24586944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221.
    Di Martino MT; Arbitrio M; Fonsi M; Erratico CA; Scionti F; Caracciolo D; Tagliaferri P; Tassone P
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861748
    [No Abstract]   [Full Text] [Related]  

  • 6. Phospholamban Inhibition by a Single Dose of Locked Nucleic Acid Antisense Oligonucleotide Improves Cardiac Contractility in Pressure Overload-Induced Systolic Dysfunction in Mice.
    Morihara H; Yamamoto T; Oiwa H; Tonegawa K; Tsuchiyama D; Kawakatsu I; Obana M; Maeda M; Mohri T; Obika S; Fujio Y; Nakayama H
    J Cardiovasc Pharmacol Ther; 2017 May; 22(3):273-282. PubMed ID: 27811197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides.
    Yamamoto T; Mukai Y; Wada F; Terada C; Kayaba Y; Oh K; Yamayoshi A; Obika S; Harada-Shiba M
    Pharmaceutics; 2021 May; 13(6):. PubMed ID: 34072682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LNA-mediated microRNA silencing in non-human primates.
    Elmén J; Lindow M; Schütz S; Lawrence M; Petri A; Obad S; Lindholm M; Hedtjärn M; Hansen HF; Berger U; Gullans S; Kearney P; Sarnow P; Straarup EM; Kauppinen S
    Nature; 2008 Apr; 452(7189):896-9. PubMed ID: 18368051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-miR as a novel approach.
    Nedaeinia R; Sharifi M; Avan A; Kazemi M; Rafiee L; Ghayour-Mobarhan M; Salehi R
    Cancer Gene Ther; 2016 Aug; 23(8):246-53. PubMed ID: 27364574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. microRNA-181a-5p antisense oligonucleotides attenuate osteoarthritis in facet and knee joints.
    Nakamura A; Rampersaud YR; Nakamura S; Sharma A; Zeng F; Rossomacha E; Ali SA; Krawetz R; Haroon N; Perruccio AV; Mahomed NN; Gandhi R; Rockel JS; Kapoor M
    Ann Rheum Dis; 2019 Jan; 78(1):111-121. PubMed ID: 30287418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LNA-anti-miR-150 ameliorated kidney injury of lupus nephritis by inhibiting renal fibrosis and macrophage infiltration.
    Luan J; Fu J; Chen C; Jiao C; Kong W; Zhang Y; Chang Q; Wang Y; Li D; Illei GG; Kopp JB; Pi J; Zhou H
    Arthritis Res Ther; 2019 Dec; 21(1):276. PubMed ID: 31829247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-361-3p is a potent therapeutic target for oral squamous cell carcinoma.
    Ogawa H; Nakashiro KI; Tokuzen N; Kuribayashi N; Goda H; Uchida D
    Cancer Sci; 2020 May; 111(5):1645-1651. PubMed ID: 32086979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo activity of miR-92a-Locked Nucleic Acid (LNA)-Inhibitor against endometrial cancer.
    Torres A; Kozak J; Korolczuk A; Wdowiak P; Domańska-Glonek E; Maciejewski R; Torres K
    BMC Cancer; 2016 Oct; 16(1):822. PubMed ID: 27782822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a bioanalytical method for quantification of LNA-i-miR-221, a 13-mer oligonucleotide, in rat plasma using LC-MS/MS.
    Franzoni S; Vezzelli A; Turtoro A; Solazzo L; Greco A; Tassone P; Di Martino MT; Breda M
    J Pharm Biomed Anal; 2018 Feb; 150():300-307. PubMed ID: 29268195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locked nucleic acid-inhibitor of miR-205 decreases endometrial cancer cells proliferation in vitro and in vivo.
    Torres A; Kozak J; Korolczuk A; Rycak D; Wdowiak P; Maciejewski R; Torres K
    Oncotarget; 2016 Nov; 7(45):73651-73663. PubMed ID: 27655663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEI-complexed LNA antiseeds as miRNA inhibitors.
    Thomas M; Lange-Grünweller K; Dayyoub E; Bakowsky U; Weirauch U; Aigner A; Hartmann RK; Grünweller A
    RNA Biol; 2012 Aug; 9(8):1088-98. PubMed ID: 22894918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide.
    Fluiter K; Frieden M; Vreijling J; Rosenbohm C; De Wissel MB; Christensen SM; Koch T; Ørum H; Baas F
    Chembiochem; 2005 Jun; 6(6):1104-9. PubMed ID: 15861430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LNA Inhibitor in microRNA miR-23b as a Potential Anti-proliferative Option in Human Hepatocellular Carcinoma.
    Najafi Z; Sharifi M; Javadi G
    J Gastrointest Cancer; 2020 Mar; 51(1):109-115. PubMed ID: 30815771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LNA-i-miR-221 activity in colorectal cancer: A reverse translational investigation.
    Ali A; Grillone K; Ascrizzi S; Caridà G; Fiorillo L; Ciliberto D; Staropoli N; Tagliaferri P; Tassone P; Di Martino MT
    Mol Ther Nucleic Acids; 2024 Jun; 35(2):102221. PubMed ID: 38868363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of different chemically modified inhibitors of miR-199b in vivo.
    Duygu B; Juni R; Ottaviani L; Bitsch N; Wit JBM; de Windt LJ; da Costa Martins PA
    Biochem Pharmacol; 2019 Jan; 159():106-115. PubMed ID: 30452907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.